Active metabolites resulting from decarboxylation, reduction and ester hydrolysis of parent drugs
- I. Hartyánszky,
- H. Kalász(corresponding author),
- E. Adeghate,
- Zs Gulyás,
- M. Y. Hasan,
- K. Tekes
- Semmelweis University,
- United Arab Emirates University,
- Thalesnano, Inc.
Abstract
Decarboxylation, reduction and hydrolysis can yield active metabolites from the parent drug. Major therapeutic indications and metabolic routes of these drugs are reviewed. Changes in the logP values (determined and calculated) from the parent drug to the active metabolite show certain characteristics in comparison to other phase I metabolic alterations. Metabolic decarboxylation of parent drug is commonly associated with increase in lipophilicity. However, in some cases, decarboxylation may cause a reduction in lipophilicity. Ester hydrolysis generally unmasks either the polar carboxylic or hydroxyl group with the outcome of an increase in hydrophilicity. On the contrary, hydrolysis of phosphate ester means a huge increase in the lipophilic character of the drug, as the highly polar phosphate group is removed.
Research Output Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages 835-862 (28 pages)Journal (Volume, Issue Number)
Current Drug Metabolism (Volume 13, Issue 6)Publication milestones
- Published - 07/2012
Publication status
ISSN
1389-2002Publication IDs
- Scopus: 84863655870
- PubMed: 22571480
Documents and links
Publication metrics
Metrics
PlumX, opens in new tab
Sustainable Development Goals
- SDG 3 Good Health and Well
